234 related articles for article (PubMed ID: 32470492)
21. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
[TBL] [Abstract][Full Text] [Related]
22. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
Oshima M; Jardine MJ; Agarwal R; Bakris G; Cannon CP; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Lim SK; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Perkovic V; Heerspink HJL
Kidney Int; 2021 Apr; 99(4):999-1009. PubMed ID: 33316282
[TBL] [Abstract][Full Text] [Related]
23. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
Weir MR; Gogate J; Damaraju CV; Correa-Rotter R; Mahaffey KW
Diabetes Obes Metab; 2022 Jan; 24(1):12-20. PubMed ID: 34463423
[TBL] [Abstract][Full Text] [Related]
24. Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
Miyamoto S; Heerspink HJL; de Zeeuw D; Toyoda M; Suzuki D; Hatanaka T; Nakamura T; Kamei S; Murao S; Hida K; Ando S; Akai H; Takahashi Y; Koya D; Kitada M; Sugano H; Nunoue T; Nakamura A; Sasaki M; Nakatou T; Fujimoto K; Kawanami D; Wada T; Miyatake N; Yoshida M; Shikata K;
Diabetes Obes Metab; 2022 Aug; 24(8):1429-1438. PubMed ID: 35491532
[TBL] [Abstract][Full Text] [Related]
25. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B
Diabetologia; 2019 Oct; 62(10):1854-1867. PubMed ID: 31399845
[TBL] [Abstract][Full Text] [Related]
26. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
Oshima M; Neal B; Toyama T; Ohkuma T; Li Q; de Zeeuw D; Heerspink HJL; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V
J Am Soc Nephrol; 2020 Oct; 31(10):2446-2456. PubMed ID: 32694216
[TBL] [Abstract][Full Text] [Related]
27. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
Ohkuma T; Van Gaal L; Shaw W; Mahaffey KW; de Zeeuw D; Matthews DR; Perkovic V; Neal B
Diabetes Obes Metab; 2020 Apr; 22(4):530-539. PubMed ID: 31729107
[TBL] [Abstract][Full Text] [Related]
29. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
Carbone S; Dixon DL
Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
32. Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
Sen T; Li J; Neuen BL; Arnott C; Neal B; Perkovic V; Mahaffey KW; Shaw W; Canovatchel W; Hansen MK; Heerspink HJL
J Am Heart Assoc; 2021 Dec; 10(23):e021661. PubMed ID: 34854308
[TBL] [Abstract][Full Text] [Related]
33. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
Seidu S; Kunutsor SK; Cos X; Gillani S; Khunti K;
Prim Care Diabetes; 2018 Jun; 12(3):265-283. PubMed ID: 29482993
[TBL] [Abstract][Full Text] [Related]
34. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
35. [Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE].
Scheen AJ
Rev Med Liege; 2019 Oct; 74(10):508-513. PubMed ID: 31609553
[TBL] [Abstract][Full Text] [Related]
36. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
Koshino A; Schechter M; Sen T; Vart P; Neuen BL; Neal B; Arnott C; Perkovic V; Ridker PM; Tuttle KR; Hansen MK; Heerspink HJL
Diabetes Care; 2022 Nov; 45(11):2644-2652. PubMed ID: 36134918
[TBL] [Abstract][Full Text] [Related]
38. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
39. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
Charytan DM; Mahaffey KW; Jardine MJ; Cannon CP; Neal B; Lambers Heerspink HJ; Agarwal R; Bakris GL; de Zeeuw D; Levin A; Pollock C; Zhang H; Zinman B; Rosenthal N; Perkovic V; Di Tanna GL; Yu J; Rogers K; Arnott C; Wheeler DC
BMJ Open Diabetes Res Care; 2023 Jun; 11(3):. PubMed ID: 37311602
[TBL] [Abstract][Full Text] [Related]
40. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
Arnott C; Huang Y; Neuen BL; Di Tanna GL; Cannon CP; Oh R; Edwards R; Kavalam M; Rosenthal N; Perkovic V; Jardine MJ; Mahaffey K; Neal B
Diabetes Obes Metab; 2020 Oct; 22(10):1753-1766. PubMed ID: 32436638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
